No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IBIO iBio Inc
- 2.2549
- +0.1049+4.88%
Trading Jul 22 14:41 ET
19.45MMarket Cap-887P/E (TTM)
2.2650High2.1300Low35.08KVolume2.1800Open2.1500Pre Close76.94KTurnover0.53%Turnover RatioLossP/E (Static)8.62MShares15.988052wk High0.78P/B14.94MFloat Cap1.021452wk Low--Dividend TTM6.62MShs Float30300.0000Historical High--Div YieldTTM6.28%Amplitude1.0214Historical Low2.1930Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
IBio Price Target Announced at $3.60/Share by Brookline Capital
IBio Price Target Announced at $3.60/Share by Brookline
IBio Initiated at Buy by Brookline Capital
IBio Initiated at Buy by Brookline
Brookline Capital Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $3.6
Brookline Capital analyst Kemp Dolliver initiates coverage on $iBio Inc(IBIO.US)$ with a buy rating, and sets the target price at $3.6.According to TipRanks data, the analyst has a success rate of 29.
IBio Files $150M Mixed Shelf Offering
Express News | Ibio Inc Files for Mixed Shelf of up to $150 Mln - SEC Filing
Express News | IBio Receives Notice of Allowance for US Patent Application 17/821,295 Titled "Anti-CD-25 Antibody for the Treatment of Cancer"
Comments
$iBio Inc(IBIO.US$have news no volume sad
$iBio Inc(IBIO.US$ iBio Receives Notice of Allowance for US Patent Application 17/821,295 Titled "Anti-CD-25 Antibody for the Treatment of Cancer"
Benzinga06/26/2024 11:30
Benzinga06/26/2024 11:30
$iBio Inc(IBIO.US$ Reuters· 1 min ago1min
ibio Inc - Ibio CDMO LLC Entered Into Purchase, Sale Agreement, Dated as of May 17, With Board of Regents of Texas a&M University System, property will be sold to board of regents for 8.5 million
ibio Inc - Ibio CDMO LLC Entered Into Purchase, Sale Agreement, Dated as of May 17, With Board of Regents of Texas a&M University System, property will be sold to board of regents for 8.5 million
$iBio Inc(IBIO.US$
Summary by Moomoo AI
iBio Inc, a preclinical stage biotechnology company, has filed a prospectus related to the resale of up to 10,574,556 shares of common stock by identified selling stockholders. These shares include 2,701,315 outstanding shares held by the selling stockholders, 2,585,963 shares issuable upon the exercise of pre-funded warrants, and 5,287,278 shares issuable upon the exercise of outstanding warrants. The selling stockholders acquired these shares a...
Summary by Moomoo AI
iBio Inc, a preclinical stage biotechnology company, has filed a prospectus related to the resale of up to 10,574,556 shares of common stock by identified selling stockholders. These shares include 2,701,315 outstanding shares held by the selling stockholders, 2,585,963 shares issuable upon the exercise of pre-funded warrants, and 5,287,278 shares issuable upon the exercise of outstanding warrants. The selling stockholders acquired these shares a...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Trytosaveabit : Sad isn’t it, how one can get a patent and goes 100%+ and another gets a very similar patent ( meaning in same field/type ) and can’t even get a bit of volume? Hehehe! In its defense though. Sometimes I’ve seen patent news take a day or 3 to move a tickers price? GL to ya